Compare peptides
Factual side-by-side comparisons — chemical identity, literature volume, and attributed independent-test coverage. We don't rank one above another; the data is the comparison.
Semaglutide vs TirzepatideTirzepatide vs RetatrutideRetatrutide vs SemaglutideCagrilintide vs SemaglutideSemaglutide vs LiraglutideBPC-157 vs TB-500CJC-1295 vs IpamorelinSermorelin vs CJC-1295Ipamorelin vs GHRP-6GHRP-6 vs HexarelinSermorelin vs TesamorelinTesamorelin vs CJC-1295MOTS-c vs HumaninSelank vs SemaxMelanotan II vs Bremelanotide
Comparison guides
Longer-form, sourced write-ups that go beyond the spec table — head-to-head context on mechanism, research, and where each compound stands.
Bachem vs PolyPeptide vs AmbioPharm: CDMOsA neutral look at three major pharma-grade peptide CDMOs: Bachem, PolyPeptide Group, and AmbioPharm. We cover country of operation, ownership, manufacturing footprint, and publicly stated regulatory credentials, as of mid-2026.BPC-157 vs TB-500BPC-157 and TB-500 are the two most-discussed repair peptides in the research literature. Both are studied for tissue effects, but they come from different sources and are described by different proposed mechanisms. Neither is approved for human use, and the FDA restricted both from US compounding in 2023.Cagrilintide vs SemaglutideA neutral look at how cagrilintide and semaglutide work differently, what published research reports about their combination, and why they are being studied together as CagriSema.CJC-1295 vs Sermorelin vs IpamorelinA side-by-side look at how CJC-1295, Sermorelin, and Ipamorelin differ in mechanism, half-life, and selectivity, based on what the research literature reports.Finnrick vs PeptideBenchmark vs VialAudit vs PeptigrityA head-to-head breakdown of four peptide vendor-rating services: what each measures, how they score, and whether they are independent, plus how peptideone.org weighs them. Aggregated from each service's own published methodology as of mid-2026.